本帖最后由 老马 于 2012-1-13 21:20 编辑
5 ^7 ~' P( ~& ?" ]3 z7 B R% Z/ y) D: {
爱必妥和阿瓦斯丁的比较* q: J4 M5 F0 u0 M! s% O9 G
& r$ Z( c+ _. ?0 jhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/
m/ Q$ s3 t* I7 a
) o8 G# S: j7 G7 O
. @. B: f- \" |0 G6 e
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
0 ~; n* y: j' q==================================================
7 O2 W5 e2 V- c5 Z. i1 [Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
3 V" r( J$ z: {* hPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.$ M7 v9 g2 _/ O5 ?: U
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. X* W0 @8 i2 D! N0 Q
|